XT
OVID icon

XTX Topco’s Ovid Therapeutics OVID Stock Holding History

XTX Topco’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$92.4K Sell
34,340
-79,053
-70% -$204K ﹤0.01% 3553
2026
Q1 		$252K Sell
113,393
-75,063
-40% -$134K ﹤0.01% 2638
2025
Q4 		$307K Buy
188,456
+5,158
+3% +$7.95K 0.01% 2045
2025
Q3 		$238K Buy
183,298
+104,878
+134% +$90.9K 0.01% 1700
2025
Q2 		$25.9K Sell
78,420
-14,734
-16% -$4.44K ﹤0.01% 2129
2025
Q1 		$29.1K Buy
+93,154
New +$57.3K ﹤0.01% 2088
2024
Q4 		– Sell
-38,230
Closed -$45.1K – 2763
2024
Q3 		$45.1K Buy
38,230
+12,076
+46% +$12.6K ﹤0.01% 1709
2024
Q2 		$20.1K Buy
+26,154
New +$72.8K ﹤0.01% 1612
2021
Q3 		– Sell
-50,569
Closed -$198K – 964
2021
Q2 		$198K Buy
+50,569
New +$200K 0.07% 567

Other funds holding OVID

JT
Jupiter Topco New York $245B AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

XTX Topco's OVID Position: Q2 2026 in Review

XTX Topco reduced its Ovid Therapeutics (OVID) stake by 70% in Q2 2026, selling an estimated $204K and leaving 34,340 shares worth $92.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3553.

XTX Topco first reported a position in OVID in Q2 2021 and has held it in 9 quarters since. The position peaked at $307K in Q4 2025. 130 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

  • XTX Topco held 34,340 shares of Ovid Therapeutics worth $92.4K as of Q2 2026.
  • XTX Topco sold 79,053 Ovid Therapeutics shares in Q2 2026, an estimated $204K.
  • Ovid Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q2 2026, its #3553 holding.
  • XTX Topco first reported a position in Ovid Therapeutics in Q2 2021 and has held it in 9 quarters since.
  • XTX Topco's Ovid Therapeutics position peaked at $307K in Q4 2025.
  • 130 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.